TY - JOUR
T1 - A case report of atezolizumab induced tumor lysis syndrome
AU - Fa’ak, Faisal
AU - Vanegas, Diego
AU - Osei, Kofi M.
N1 - Publisher Copyright:
© Am J Case Rep, 2019.
PY - 2019
Y1 - 2019
N2 - Objective: Background: Case Report: Conclusions: Unusual clinical course Advanced urothelial carcinoma has been associated with poor prognosis due to high resistance to chemotherapy and radiation until immunotherapeutic agents, such as atezolizumab, emerged as an option and have shown improved survival. However, atezolizumab is associated with side effects, which were mainly autoimmune. In this case study, we report on a rare case of atezolizumab-induced tumor lysis syndrome. A 67-year-old female with a primary diagnosis of metastatic urothelial carcinoma who presented to the emergency department with generalized weakness associated with nausea and vomiting 8 days after her first cycle of atezolizumab. Laboratory values showed hyperphosphatemia, hyperuricemia, hypocalcemia, and acute kidney injury consistent with tumor lysis syndrome. In our report, we highlight tumor lysis syndrome as a potential reaction to atezolizumab; a condition that requires prophylaxis and close laboratory monitoring.
AB - Objective: Background: Case Report: Conclusions: Unusual clinical course Advanced urothelial carcinoma has been associated with poor prognosis due to high resistance to chemotherapy and radiation until immunotherapeutic agents, such as atezolizumab, emerged as an option and have shown improved survival. However, atezolizumab is associated with side effects, which were mainly autoimmune. In this case study, we report on a rare case of atezolizumab-induced tumor lysis syndrome. A 67-year-old female with a primary diagnosis of metastatic urothelial carcinoma who presented to the emergency department with generalized weakness associated with nausea and vomiting 8 days after her first cycle of atezolizumab. Laboratory values showed hyperphosphatemia, hyperuricemia, hypocalcemia, and acute kidney injury consistent with tumor lysis syndrome. In our report, we highlight tumor lysis syndrome as a potential reaction to atezolizumab; a condition that requires prophylaxis and close laboratory monitoring.
KW - Immunotherapy
KW - Programmed Cell Death 1 Ligand 2 Protein
KW - Tumor Lysis Syndrome
KW - Urinary Bladder Neoplasms
UR - http://www.scopus.com/inward/record.url?scp=85067194280&partnerID=8YFLogxK
U2 - 10.12659/AJCR.915351
DO - 10.12659/AJCR.915351
M3 - Article
C2 - 31160547
AN - SCOPUS:85067194280
SN - 1941-5923
VL - 20
SP - 785
EP - 789
JO - American Journal of Case Reports
JF - American Journal of Case Reports
ER -